Left ventricular systolic function following alcohol septal ablation for symptomatic hypertrophic cardiomyopathy

Am J Cardiol. 2014 Apr 15;113(8):1401-4. doi: 10.1016/j.amjcard.2014.01.417. Epub 2014 Jan 31.

Abstract

Because alcohol septal ablation (ASA) for the treatment of symptomatic hypertrophic cardiomyopathy (HC) with left ventricular (LV) outflow tract (LVOT) obstruction results in a myocardial infarct of up to 10% of ventricular mass, LV systolic function could decline over time. We evaluated LV function during longitudinal follow-up in a cohort of patients who underwent ASA. We studied 145 consecutive patients with HC that underwent 167 ASA procedures from 2002 to 2011. Echocardiographic follow-up was available in 139 patients (96%). Echocardiographic indexes included LV ejection fraction (LVEF), mitral regurgitation severity, systolic anterior motion of the anterior mitral leaflet, and resting and provoked LVOT gradients. All patients had a baseline LVEF of >55%. LVEF was preserved in 97.1% of patients over a mean follow-up time of 3.1±2.3 years (maximum 9.7). Mild LV systolic dysfunction was observed (LVEF range 44% to 54%) in only 4 patients. Mitral regurgitation severity improved in 67% (n=112 of 138 with complete data). Resting LVOT gradient declined from a mean of 75 to 19 mm Hg (p<0.001), and provoked gradient declined from a mean of 101 to 33 mm Hg (p<0.001). New York Heart Association class improved from a mean of 2.9±0.4 to 1.3±0.5 (p<0.001). In conclusion, LV systolic function is only mildly reduced in a minority of patients after ASA for symptomatic HC; other echocardiographic and functional measures were significantly improved.

Publication types

  • Clinical Trial
  • Comparative Study
  • Multicenter Study

MeSH terms

  • Cardiomyopathy, Hypertrophic / diagnosis
  • Cardiomyopathy, Hypertrophic / physiopathology*
  • Cardiomyopathy, Hypertrophic / therapy
  • Echocardiography
  • Ethanol / administration & dosage*
  • Female
  • Follow-Up Studies
  • Heart Septum / diagnostic imaging
  • Heart Septum / drug effects*
  • Humans
  • Injections
  • Male
  • Middle Aged
  • Prospective Studies
  • Solvents / administration & dosage
  • Treatment Outcome
  • Ventricular Function, Left / physiology*

Substances

  • Solvents
  • Ethanol